Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Elizabeth Holt

Endocrinology, Diabetes & Metabolism Raleigh, NC Medical Doctor

NPI 1215905674 CMS profile 100053

2709 Blue Ridge Rd, Suite 320, Raleigh, NC 27607

Open in the dashboard

General payments

$167,381

296 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Elizabeth Holt of Raleigh, NC is reported in the CMS Open Payments database as having received $167,381 across 296 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $122 1
2022 General $98 2
2021 General $16 1
2020 General $2,000 1
2019 General $165,145 291

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Elizabeth Holt
  • Endocrinology, Diabetes & Metabolism median
  • Middle half of Endocrinology, Diabetes & Metabolism
  • National median

In program year 2025, general payments to Elizabeth Holt were reported at $0. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.

Show as a table
Year Elizabeth Holt Endocrinology, Diabetes & Metabolism median Middle half National median
2019 $165,145 $494 $123–$2,253 $163
2020 $2,000 $335 $85–$1,841 $114
2021 $16 $398 $88–$1,981 $132
2022 $98 $364 $88–$1,568 $149
2023 $122 $420 $113–$1,614 $160
2024 $0 $440 $121–$1,646 $164
2025 $0 $507 $135–$1,838 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Lilly USA, LLC $96,792 191 payments
  2. Novo Nordisk Inc $40,861 43 payments
  3. AbbVie, Inc. $25,912 39 payments
  4. Amgen Inc. $3,412 12 payments
  5. LifeScan, Inc. $122 1 payment
  6. Senseonics, Incorporated $89 3 payments
  7. Shire North American Group Inc $63 1 payment
  8. Horizon Therapeutics plc $48 1 payment
  9. Abbott Laboratories $39 2 payments
  10. Insulet Corporation $16 1 payment
  11. Other $27 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $123,761 75 payments
  2. Travel and Lodging $23,791 114 payments
  3. Consulting Fee $14,080 3 payments
  4. Food and Beverage $3,741 102 payments
  5. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $2,000 1 payment
  6. Education $8 1 payment
Products named General payments · program years 2019–2023
  1. TRULICITY $83,440 161 payments
  2. Synthroid $23,074 35 payments
  3. Ozempic $18,154 20 payments
  4. Victoza $11,856 11 payments
  5. Tresiba $7,249 5 payments
  6. Repatha $3,148 9 payments
  7. Xultophy 100/3.6 $2,498 3 payments
  8. EVENITY $138 2 payments
  9. Prolia $138 2 payments
  10. Eversense $89 3 payments
  11. Other $259 10 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

296 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Endocrinology, Diabetes & Metabolism in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record